ClinicalTrials.gg
RecruitingNCT06755008RepCOPDiPSUpdated May 12, 2026

Benefits of Epithelial Repair in COPD by Induced Pluripotent Stem Cells (iPS)

An interventional study of bronchial fibroscopy in Pulmonary Disease, Chronic Obstructive, sponsored by University Hospital, Montpellier. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-12.

Sponsored by University Hospital, Montpellier · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Pulmonary Disease, Chronic Obstructive by University Hospital, Montpellier — 2 open to participants now, 2 under way, none of them phase 3. Pulmonary Disease, Chronic Obstructive · University Hospital, Montpellier.

Planned enrollment
6th of 11
50 · median 50
Started
2025
the only one that year
No phase
9 of 18
1 open now
Registered
18th of 18
by date

Among the 18 studies in Pulmonary Disease, Chronic Obstructive by University Hospital, Montpellier, this one is the 6th largest by planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2025, is one of 9 with no phase, and was the 18th registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

2 of the 18 studies in Pulmonary Disease, Chronic Obstructive by University Hospital, Montpellier are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Pulmonary Disease, Chronic Obstructive by University Hospital, Montpellier, or all of them as a file.
02

Study summary

The aim of this interventional, cross-sectional and pathophysiological experimental study is to evaluate the potential of a patient's induced pluripotent stem (iPS) cells, used prior to the re-differentiation stage, to enable ex vivo repair of the injured epithelium in patients with chronic obstructive pulmonary disease (COPD), smokers without COPD and non-smoking controls.

The main questions it aims to answer are:

  • to evaluate the repair capacity of bronchial epithelium in COPD subjects, using a model of bronchial epithelium reconstituted in air/liquid interface culture and the iPS model.
  • epithelia repair capacities in normal or aberrant situations, as well as the time required for this repair, and to determine the involvement of grafted iPS cells in epithelia repair in cultured control subjects, smokers without COPD and COPD patients.

Researchers will compare 3 groups of participants (COPD patients, smokers without COPD and non-smokers without COPD) for epithelial repair efficacy between non-grafted ALI cultures and ALI cultures grafted with iPS cells, in order to assess their contribution to epithelial repair.

Participants will undergo a bronchial fibroscopy (for clinical indications) with two additional biopsies specific to the study.

This research could lead to breakthroughs in cell-based therapies for COPD, with long-term implications for epigenetic treatments and in vivo applications.

Read the detailed description

Recently, the research team were able to show that there is a deficiency in a particular subtype of club cells destined to become ciliated in COPD, which would explain the inversion of the ciliated cell/caliciform cell ratio and therefore in the formation of the mucous plugs involved in bronchiolar obstruction.

iPS (induced pluripotent stem cells) represent a major biological breakthrough that has been awarded a Nobel Prize. They offer the advantage of being pluripotent, capable of multiplying endlessly, and thus of differentiating into any other cell type, or even organ, in short, embryogenesis. Researchers have developed a protocol for differentiating iPS cells into bronchial epithelia, with interesting success. These epithelia reconstituted in an air-liquid interface (iALI) reproduce all the characteristics of epithelia in vivo, in particular with the presence of all cell subtypes.

The research team hypothesizes that a patient's iPS cells, used before the re-differentiation stage, will enable ex vivo repair of his damaged epithelium.

The expected results of this project will be to validate the in vitro model of epithelial cell aggression in air-liquid interface (ALI) cultures, and to determine the feasibility of seeding iPS-derived epithelial cells. ALI epithelia from COPD patients would repair better or even normally thanks to iPS.

Ultimately, this project could be a potential therapy targeting epigenetics, and why not a cell therapy.

03

Conditions studied

  • Pulmonary Disease, Chronic Obstructive

Keywords

  • COPD
  • bronchial epithelium
  • iPS
  • repair
  • Club cell
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

General Inclusion Criteria

  • Male and female participants aged 18 years or older.
  • Participants with a bronchoscopy indication determined by a pulmonologist (e.g., follow-up exploration, nodule investigation, hemoptysis, cough, sputum production, recurrent bronchitis, or differential diagnosis).

Group 1 Inclusion Criteria:

  • Current or former smokers (≥10 pack-years).
  • Diagnosed with COPD: /FVC \< 0.7 (confirmed by spirometry available in the medical file within the past year).

Group 2 Inclusion Criteria: Smokers without COPD (n=10)

  • Current or former smokers (≥10 pack-years).
  • No obstructive ventilatory disorder identified by clinical examination and/or (FEV1/FVC > 0.7 and FEV1 > 70% of predicted values) confirmed by spirometry within the past year.

Group 3 Inclusion Criteria: Non-smoker controls (n=10)

  • Never-smokers or former smokers who quit more than 10 years ago (\<10 pack-years).
  • No obstructive ventilatory disorder identified by clinical examination and/or (FEV1/FVC > 0.7 and FEV1 > 70% of predicted values) confirmed by spirometry within the past year.

Exclusion Criteria:

  • Participant with extensive neoplastic disease.
  • Participant with another progressive pulmonary condition (e.g., asthma, tuberculosis, interstitial lung disease, active or recent pulmonary infection).
  • Participant consuming illicit drugs or alcohol.
  • Individual deprived of liberty (by judicial or administrative decision, or under involuntary hospitalization).
  • Individual currently enrolled in another research study with an ongoing exclusion period.
  • Participant with recent psychiatric disorders (e.g., involuntary hospitalization, mental health conditions preventing , or requiring immediate medical intervention).
  • Adult under legal protection (e.g., guardianship, curatorship, or judicial protection).
  • Participant unable to provide informed consent.
  • Participant not fluent in French and without a trusted person to assist with comprehension.
  • Participant not affiliated with or covered by a social security system.
  • Pregnant or breastfeeding women.
  • Participant refusing to provide consent after being informed.
  • Participant unable or incapable of expressing consent.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    smoker with COPD

    Bronchial biopsy performed during a planned bronchial fibroscopy as part of their disease management.

    Procedure: bronchial fibroscopy

  • Active comparator
    smoker without COPD

    Bronchial biopsy performed during a planned bronchial fibroscopy as part of their disease management.

    Procedure: bronchial fibroscopy

  • Active comparator
    healthy non-smoking subject

    Bronchial biopsy performed during a planned bronchial fibroscopy as part of their disease management.

    Procedure: bronchial fibroscopy

Interventions

  • Procedurebronchial fibroscopy

    2 bronchial biopsies will be taken during bronchial fibroscopy

06

What researchers measure

Primary outcomes

  1. The main objective is to evaluate the repair capacity of the bronchial epithelium of COPD subjects using the reconstituted bronchial epithelium model in air/liquid interface culture and the iPS model.

    Percentage of repair at 24 hours post-lesion of ALI cultures vs. the same ALI cultures "grafted with iPS". This percentage will be determined by the surface area of the culture reconstructed after scratching divided by the surface area initially scratched.

    Time frame: Day 1

Secondary outcomes

  1. comparison of % repair of post-scratch cultures in the presence or absence of IPS between the 3 groups

    Calculation of the percentage of repair at 48 hours, 72 hours and at 7 days post-scratch. This percentage will be determined by the surface area of the culture rebuilt after scratching divided by the surface area initially scratched.

    Time frame: Day 2, Day 3 and day 7

  2. Comparison of transepithelial electrical resistances between groups

    Verification of the integrity of the bronchial epithelium obtained by measuring the transepithelial electrical resistance. (expressed as Ω/cm2 at each time point).

    Time frame: Day 2, Day 3 and day 7

  3. Determining the proportion of GFP-tagged iPS cells vs. native cells in lesion repair:

    Cell density measurements (% GFP cells/total cells) by microscopy at each time point

    Time frame: Day 2, Day 3 and day 7

  4. Phenotyping of native and GFP+ iPS populations by immunofluorescent labeling of different cell types (ciliated cells, mucus cells, club cells, basal cells)

    immunofluorescence will be used to assess the density of basal, club, ciliated and caliciform cells; the release of key proinflammatory cytokines classically implicated in COPD will be assayed in the supernatant of these cultures.

    Time frame: Day 2, Day 3 and day 7

  5. Comparison of the transcriptomic profile for each cell subtype obtained after sorting native cells and GFP+ iPS cells by flow cytometry.

    Comparison of the transcriptomic profile by ANOVA analysis of the 10 most highly expressed genes between native cells and IPS cells.

    Time frame: Day 2, Day 3 and day 7

  6. Comparison of transcriptomic profile between ungrafted and grafted ALI.

    Comparison of the transcriptomic profile by ANOVA analysis of the 10 most highly expressed genes

    Time frame: Day 2, Day 3 and day 7

  7. ciliated cell/caliciform ratio to check whether the deficient club cell subtype is restored by this technique

    the ciliated cell/caliciform ratio

    Time frame: Day 2, Day 3 and day 7

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Jan 2028, 34 months after the start.

Of 1,099 non-industry interventional studies with no phase under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 34 months is above that.

Counting every sponsor, half of 1,187 studies reached it within 22 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2024
First posted
Jan 1, 2025
StartActual
Feb 19, 2025
Primary completionEst.
Jan 1, 2028
CompletionEst.
Jan 1, 2028
Last update
May 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06755008
Responsible party
Sponsor
First posted
Jan 1, 2025
Start date
Feb 19, 2025
Primary completion
Jan 1, 2028 (estimated)
Completion
Jan 1, 2028 (estimated)
Last update
May 12, 2026

Study contacts

Isabelle VACHIER, PhD
Contact
isabelle.vachier@medbiomed.fr
(0)467042020 ext. +33
Mathilde VOLPATO, MD
principal investigator · University Hospital, Montpellier

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion